Comparison of Ceftolozane-Tazobactam and Ceftazidime-Avibactam in the Treatment of Multidrug-Resistant/Difficult-to-Treat Resistant Pseudomonas aeruginosa Infections: A Systematic Review and Meta-analysis
Clinical Infectious Diseases · 02.09.2026 · 83 (2) · e270-e281
DOI: 10.1093/cid/ciag194 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Clinical Infectious Diseases, online erschienen am 18.03.2026. Verfasst von Milo Gatti und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Azabicyclo Compounds, Ceftazidime, Cephalosporins. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Ceftolozane-tazobactam and ceftazidime-avibactam are considered first-line treatment for multidrug-resistant (MDR) and/or difficult-to-treat resistant (DTR) Pseudomonas aeruginosa infections. Conflicting results in terms of clinical outcome and resistance development emerged from real-world comparative studies. We performed a systematic review with meta-analysis to compare ceftolozane-tazobactam and ceftazidime-avibactam in the treatment of MDR/DTR P. aeruginosa infections.
Methods
Two authors independently searched PubMed-MEDLINE and Scopus databases from inception to 18 November 2025 to retrieve studies comparing ceftolozane-tazobactam versus ceftazidime-avibactam in the management of MDR/DTR P. aeruginosa infections. Clinical cure was set as the primary outcome, whereas 90-day resistance development, microbiological failure, and the 30-day mortality rate were set as the secondary outcomes. Meta-analysis was performed by pooling the odds ratios (ORs) retrieved from studies providing adjustment for confounders by means of a random-effects model with the inverse variance method. The risk of bias in the included studies was independently assessed using the RoB 2.0 and the ROBINS-I tools.
Results
Among a total of 1193 articles screened, 6 observational studies were retrieved and included (n = 1161; 644 receiving ceftolozane-tazobactam vs 517 receiving ceftazidime-avibactam). Ceftolozane-tazobactam showed a higher clinical cure rate than ceftazidime-avibactam (n = 4; OR, 1.82 [95% confidence interval, 1.10–2.99]; I2 = 25.3%). No difference emerged in terms of microbiological failure (n = 2; OR, 0.66 [95% confidence interval, .36–1.19]; I2 = 21.9%), 90-day resistance development (n = 3; OR, 1.11 [.51–2.42]; I2 = 50.0%), or 30-day mortality rate (n = 4; OR, 1.00 [.89–1.12]; I2 = 0.0%).
Conclusions
Our meta-analysis showed that, after appropriate adjustment for confounders, ceftolozane-tazobactam could grant a higher clinical cure rate than ceftazidime-avibactam in the treatment of MDR/DTR P. aeruginosa infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy.
- Clinical Pharmacology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
- Specialisation School of Clinical Pharmacology and Toxicology, Alma Mater Studiorum, University of Bologna, Bologna, Italy.
ORCID-Profile: Milo Gatti, Riccardo De Paola, Beatrice Giorgi, Federico Pea
Zitieren
APA
Gatti, M., De Paola, R., Giorgi, B., & Pea, F. (2026). Comparison of Ceftolozane-Tazobactam and Ceftazidime-Avibactam in the Treatment of Multidrug-Resistant/Difficult-to-Treat Resistant Pseudomonas aeruginosa Infections: A Systematic Review and Meta-analysis. Clinical Infectious Diseases, 83(2), e270-e281. https://doi.org/10.1093/cid/ciag194
Vancouver
Gatti M, De Paola R, Giorgi B, Pea F. Comparison of Ceftolozane-Tazobactam and Ceftazidime-Avibactam in the Treatment of Multidrug-Resistant/Difficult-to-Treat Resistant Pseudomonas aeruginosa Infections: A Systematic Review and Meta-analysis. Clinical Infectious Diseases. 2026;83(2):e270-e281. doi:10.1093/cid/ciag194
BibTeX
@article{Gatti2026,
author = {Gatti, Milo and De Paola, Riccardo and Giorgi, Beatrice and Pea, Federico},
title = {Comparison of Ceftolozane-Tazobactam and Ceftazidime-Avibactam in the Treatment of Multidrug-Resistant/Difficult-to-Treat Resistant Pseudomonas aeruginosa Infections: A Systematic Review and Meta-analysis},
journal = {Clinical Infectious Diseases},
year = {2026},
volume = {83},
number = {2},
pages = {e270--e281},
doi = {10.1093/cid/ciag194}
}
EUVIMED